MOYOM Secures EU MDR Certification for APHRANEL®, Expands European Reach
Biotechnology firm MOYOM announced it has achieved EU Medical Device Regulation (MDR) certification for its APHRANEL® product and initiated a strategic scientific collaboration with Expert2Expert.
London – Biotechnology firm MOYOM has reached two significant milestones in its European strategy. The company announced that its APHRANEL® product has received certification under the European Union's Medical Device Regulation (MDR). Concurrently, MOYOM confirmed a strategic scientific collaboration with the Expert2Expert network.
APHRANEL® is a product developed by MOYOM focused on regenerative aesthetics. Obtaining MDR certification is crucial for medical devices within the EU market, signifying adherence to stringent safety and efficacy standards.
The scientific collaboration with Expert2Expert, a network of European specialists, aims to advance the scientific understanding and application of regenerative aesthetics. This partnership is expected to accelerate the development and adoption of new treatment modalities.
MOYOM CEO Jane Doe stated the company's commitment to high standards and scientific advancement. "These achievements reinforce our position in the European regenerative aesthetics sector," Doe said.
The certification and collaboration are key components of MOYOM's European growth strategy, anticipated to unlock new business opportunities and bolster the company's research and development efforts.